Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Unichem Laboratories Limited (UNICHEMLAB.NS)
INR595.10
+13.75 (+2.37%)
IN NSE Healthcare Drug Manufacturers - Specialty & Generic
Address
Unichem Bhavan 400102
Mumbai, IN
Mumbai, IN
CEO
Scott Delaney
Website
unichemlabs.com
IPO
2002-07-01
ISIN INE351A01035
Also trades on
Bombay Stock Exchange · UNICHEMLAB.BO (INR)
National Stock Exchange of India · UNICHEMLAB.NS (INR)
Description
Unichem Laboratories Limited is an international pharmaceutical company engaged in the development, manufacturing, and commercialization of a wide array of medicinal products. The firm's portfolio features finished pharmaceutical formulations designed to treat numerous health conditions, including those related to gastroenterology, cardiovascular health, diabetes, mental health, neurological disorders, bacterial and other infectious diseases, and pain relief. Beyond these formulations, Unichem also provides active pharmaceutical ingredients (APIs) and offers contract manufacturing solutions. This enterprise was established in 1944 and operates from its corporate headquarters in Mumbai, India.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR595.10
+13.75 (+2.37%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
607.8K
Beta
0.90
Float Shares
20.06M
Free Float %
28.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.92% | -5.75% | -4.34% | +1.67% | -24.10% | -19.38% | -41.58% | -5.04% | -2.46% | +36.19% | +1,337.45% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
595.10
Quality scores
Altman Z-Score
2.76
Grey zone
Piotroski F-Score
6 / 9
Average
MOAT Score
4 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.3% Q1'26: -2.1% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+84.1% ★ Q1'26: -79.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-9.9% Q1'26: +7.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.7% Q1'26: +3.0% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.8% Q1'26: +1.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.2% ★ Q1'26: -0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×2.72× Q1'26: 2.62× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2001 actual |
Mar 2010 actual |
Mar 2011 actual |
Mar 2012 actual |
Mar 2013 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.20B
est.
|
7.47B
est: 8.00B (-6.6%)
|
8.24B
est: 8.49B (-2.9%)
|
8.75B
est: 9.04B (-3.2%)
|
10.81B
est: 10.51B (+2.8%)
|
11.33B
est: 11.63B (-2.6%)
|
12.02B
est: 12.37B (-2.9%)
|
13.35B
est: 13.71B (-2.7%)
|
15.20B
est: 15.75B (-3.5%)
|
7.78B
est: 17.52B (-55.6%)
|
11.23B
est: 19.77B (-43.2%)
|
| EBITDA |
152.96M
est.
|
1.77B
est: 816.68M (+117.3%)
|
1.58B
est: 1.85B (-14.2%)
|
1.24B
est: 1.65B (-24.8%)
|
1.82B
est: 1.43B (+26.9%)
|
1.78B
est: 2.12B (-16.2%)
|
1.01B
est: 2.90B (-65.0%)
|
1.64B
est: 1.44B (+14.1%)
|
-358.90M
est: 2.13B (-116.8%)
|
-710.16M
est: 1.55B (-145.9%)
|
145.01M
est: 1.37B (-89.4%)
|
| EBIT |
-3.67M
est.
|
1.54B
est: 1.02B (+51.2%)
|
1.29B
est: 1.61B (-19.8%)
|
938.65M
est: 1.29B (-27.1%)
|
1.36B
est: 1.02B (+32.9%)
|
1.74B
est: 1.50B (+15.8%)
|
803.71M
est: 1.41B (-42.8%)
|
1.40B
est: 669.38M (+109.3%)
|
-794.06M
est: 1.40B (-156.8%)
|
-1.22B
est: -934.72M (-30.0%)
|
-528.66M
est: -33.07M (-1,498.6%)
|
| Net Income |
311.95M
est.
|
1.23B
est: 733.52M (+67.4%)
|
951.96M
est: 1.30B (-26.9%)
|
712.58M
est: 1.01B (-29.6%)
|
1.13B
est: 829.63M (+36.5%)
|
1.69B
est: 1.25B (+35.2%)
|
753.90M
est: 1.80B (-58.1%)
|
1.08B
est: 838.17M (+28.9%)
|
1.09B
est: 1.24B (-12.5%)
|
25.45B
est: 1.21B (+2,006.2%)
|
-238.00M
est: 1.44B (-116.6%)
|
| SGA |
312.62M
est.
|
5.47B
est: -3.63M (+150,848.8%)
|
6.36B
est: 2.78B (+128.7%)
|
2.14B
est: 2.19B (-2.5%)
|
4.02B
est: 2.65B (+51.6%)
|
4.38B
est: 2.99B (+46.3%)
|
3.00B
est: 4.93B (-39.1%)
|
1.98B
est: 6.17B (-67.9%)
|
2.43B
est: 7.01B (-65.4%)
|
1.35B
est: 1.88B (-28.0%)
|
2.31B
est: 2.82B (-17.9%)
|
| EPS |
4.42
est.
|
13.66
est: 12.34 (+10.7%)
|
10.53
est: 13.28 (-20.7%)
|
7.89
est: 8.64 (-8.7%)
|
12.52
est: 12.88 (-2.8%)
|
18.69
est: 15.38 (+21.5%)
|
8.31
est: 8.85 (-6.1%)
|
11.90
est: 11.24 (+5.9%)
|
11.96
est: 13.51 (-11.5%)
|
280.59
est: 16.37 (+1,613.7%)
|
-3.38
est: 20.24 (-116.7%)
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | B+ | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-05-25 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
4.61B
OE per share TTM
65.34
Owner's Yield
18.37%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
86.7%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
205.4K
Shares Outstanding
70.41M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pabitrakumar Kalipada Bhattacharyya | MD & Director | 31M | male |
| Pradeep Kumar Bhandari | Head of Legal, Company Secretary & Compliance Officer | 11M | male |
| Sanjay Jain | Chief Financial Officer | 6M | male |
| Vinod Kumar Behl | Head of Projects & Investments | 2M | male |
| Scott Delaney | President & Chief Executive Officer of Unichem Pharmaceuticals (USA), Inc. | — | male |
| Utkarsh Patil | Chief Manufacturing Officer of Formulations | — | male |
| Prasad Joshi | Vice President of Human Resources & ER | — | male |
| Dhananjay Sathe | Chief Scientific & Compliance Officer | — | — |
| Jalesh Burye | Chief Quality & Compliance Officer | — | male |
| Bhagwat S. Dhingra | Chief Executive of Domestic Pharma | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for UNICHEMLAB.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
